Groothuis Leo Frans, a director at Viatris Inc, has been granted 2,469 deferred stock units (DSUs) as part of his compensation package. This grant is significant as it aligns the interests of directors with those of shareholders, a practice increasingly common in the pharmaceutical industry.
Viatris Inc, headquartered in Canonsburg, Pennsylvania, is a global healthcare company focused on providing access to medicines, sustainable operations, and innovative solutions. The company operates under the SIC classification of Pharmaceutical Preparations. The recent filing indicates that the grant was made in lieu of cash fees, based on the closing price of $17.72 per share of Viatris common stock on September 30, 2026.
What the Filing Says
The filing, accession number 0001140361-26-038451, states, "On September 30, 2026, the reporting person was automatically granted 2,469 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs." Each DSU is fully vested and represents the right to receive one share of common stock of Viatris.
Impact
This development may affect Viatris shareholders and the company’s overall compensation strategy. By compensating directors with stock units, Viatris aims to ensure that its leadership is motivated to enhance shareholder value.
What's Next
The filing does not say what happens next.